Brief: Inhibikase Therapeutics To Provide Trial Update For Risvodetinib On March 9
07/03/2024 15:26
March 7 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS TO PROVIDE TRIAL UPDATE FOR
RISVODETINIB
AT THE 2024 INTERNATIONAL CONFERENCE ON ALZHEIMER’S AND
PARKINSON’S DISEASES AND RELATED NEUROLOGICAL DISORDERS
Source text for Eikon: ID:nGNX1mh3N8
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share